Formulation Development
EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid & Psychedelic Therapies
Joel Latham, CEO of Incannex Healthcare, shares how the company navigates complex global regulatory pathways, building strategic collaborations, and forging a path toward commercial success.
CELL & GENE THERAPY - What the Industry Can Learn From Baby KJ About Optimizing CRISPR Development
Venkata Indurthi, PhD, believes the success of Baby KJ provides a model that could be replicated many times over to treat people with ultra-rare genetic diseases.
PLATFORM TECHNOLOGY - How PolyPid’s PLEX Unlocks the Potential of Local & Prolonged Release
Dikla Czaczkes Akselbrad asks what if, instead of relying on systemic delivery, a platform could be created that anchors drugs directly at the site of need and controls its release over weeks or months?
MAB FORMULATION & FILL-FINISH - Obstacles in Monoclonal Antibody Formulation & Fill-Finish
Nandkumar Deorkar, PhD, explores some of the key challenges in mAb formulation and fill-finish, offering practical insights to help developers navigate complexity and ensure success.
EXECUTIVE INTERVIEW - CERo Therapeutics: A Novel Approach to Treating Cancer
Chris Ehrlich, CEO of CERo Therapeutics, discusses the company’s science, clinical program, the treatment landscape, and more.
MRNA THERAPEUTICS - Strategies for Enhanced Stability, Targeted Delivery & Safe Translation
Carsten Rudolph, PhD, explores many challenges and the solutions offered by novel technology platforms, providing insight into the evolving landscape of mRNA drug development and its potential as a future transformative modality.
PhaseV Launches AI-Powered Enrollment Lab: Eliminating Guesswork & Grounding Study Design in Clinical Reality
PhaseV recently announced the launch of its new Enrollment Lab solution at the 17th Annual SCOPE Summit. A high-impact addition to the PhaseV ClinOps platform, this…
Ardena Completes Divestment of its Södertälje Drug Substance Site in Sweden to Nanologica
Ardena recently announced it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica AB. The business will operate as…
Vetter Pharma to Build New Manufacturing Site in Germany
Vetter Pharma has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany. This strategic investment marks a significant…
ENA Respiratory Announces Dosing of First Participants in Phase II Study of Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
ENA Respiratory recently announced it has dosed the first participants in its Phase II community study of INNA-051, (with the first participant dosing now completed).…
Boehringer Ingelheim’s Investigational Asset Delivers Proteinuria Reduction in Phase II Kidney Trial
Boehringer Ingelheim today announced results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor for people…
Halo Pharma to Become a Stand-Alone Drug Product Contract Development & Manufacturing Organization
Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, will become a stand-alone business as a result of the sale…
Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic in Patients with Elevated Lp(a)
Argo Biopharmaceutical Co., Ltd. recently announced the first patient has been dosed in a global Phase 2b clinical trial sponsored by Novartis evaluating DII235, also…
Vortex Biotech Opens New State-of-the-Art Laboratory at Manchester Science Park
Vortex Biotech Holdings Limited has announced the opening of its advanced laboratory facilities at Manchester Science Park. The new site significantly enhances the company’s R&D…
Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation
Nanexa AB recently announced exceptional preclinical results for its long-acting semaglutide formulation developed using the company’s proprietary PharmaShell drug delivery platform. PharmaShell encases active pharmaceutical…
iXCells Biotechnologies & Rosebud Biosciences Partner to Advance Organoid-Based Models for Rare Diseases
iXCells Biotechnologies and Rosebud Biosciences recently announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare…
Medicus Pharma Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic & Development Profile
Medicus Pharma Ltd. recently announced its subsidiary, Antev Ltd., has entered into Amendment No. 3 to its license agreement with LifeArc relating to Teverelix, an investigational next generation long-acting GnRH…
Dosing Completed in the Phase I Clinical Trial of PulseSight Therapeutics’ Treatment for Dry AMD/Geographic Atrophy
PulseSight Therapeutics SAS recently announced the completion of PST-611 Phase I clinical trial enrolment. Trial data will be presented at the 2026 ARVO Annual Meeting…
Mendra Launches With $82 Million to Acquire, Develop & Commercialize Therapeutics for High Unmet Need Rare Diseases
Mendra, Inc. recently announced its launch in conjunction with the closing of an $82 million oversubscribed Series A financing. The round was co-led by OrbiMed, 8VC,…
Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
Levicept Ltd recently announced the US FDA has accepted its Investigational New Drug (IND) application for LEVI-04. This enables the initiation of further clinical development…
